Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
Open Access
- 7 June 2019
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 28 (2) , 925-932
Abstract
Purpose The effects of chemotherapy dose intensity on survival in patients with advanced non-small-cell lung cancer (NSCLC) are poorly understood. We retrospectively analyzed dose delays/reduction, relative dose intensity (RDI), and the association between chemotherapy intensity and survival in advanced NSCLC. Methods This retrospective cohort study included adults with advanced lung cancer who received first-line myelosuppressive platinum-based chemotherapy (January 2007–December 2010) in ~ 230 US Oncology Network community practices. Dose delays ≥ 7 days, dose reductions ≥ 15%, and RDI relative to standard regimens were described. Overall survival (OS) was measured using Kaplan-Meier and Cox proportional hazard (PH) models. Results Among 3866 patients with advanced NSCLC, 32.4% experienced dose delays ≥ 7 days, 50.1% experienced dose reductions ≥ 15%, and 40.4% had RDI < 85%. Reduced RDI was also common regardless of baseline ECOG PS (ECOG PS ≥ 2, 56.2%; ECOG PS 0, 33.6%) and tumor subgroup (squamous cell carcinoma, 52.2%; adenocarcinoma, 36.0%). When stratified by chemotherapy intensity measures, significant OS differences were observed only for dose delays. Median (95% CI) OS was 1.02 years (0.96–1.12) for dose delays ≥ 7 days and 0.71 years (0.66–0.77) for dose delays < 7 days. In multivariable Cox PH analysis, dose delays ≥ 7 days (HR = 0.71; 95% CI = 0.63–0.80) and RDI ≥ 85% (HR = 1.18; 95% CI = 1.05–1.32) were significantly associated with decreased mortality. Conclusions Dose delays, dose reductions, and reduced RDI were common, and dose delays ≥ 7 days and high RDI were significantly associated with decreased mortality. These results can help identify potential risk factors and characterize the effect of chemotherapy dose modification strategies on mortality.Keywords
Funding Information
- Amgen (N/A)
This publication has 17 references indexed in Scilit:
- A review of relative dose intensity and survival in patients with metastatic solid tumorsCritical Reviews in Oncology/Hematology, 2015
- Patterns of chemotherapy‐associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort studyCancer Medicine, 2014
- Paraneoplastic syndromes associated with lung cancer Nobuhiro Kanaji, Naoki Watanabe, Nobuyuki Kita, Shuji Bandoh, Akira Tadokoro, Tomoya Ishii, Hiroaki Dobashi, Takuya MatsunagaWorld Journal of Clinical Oncology, 2014
- Non-Small-Cell Lung Cancer: Treatment of Late Stage Disease: Chemotherapeutics and New FrontiersSeminars in Interventional Radiology, 2013
- Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancerGynecologic Oncology, 2013
- Differences Between Squamous Cell Carcinoma and Adenocarcinoma of the Lung: Are Adenocarcinoma and Squamous Cell Carcinoma Prognostically Equal?Japanese Journal of Clinical Oncology, 2011
- Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated with Platinum-Doublet ChemotherapyJournal of Thoracic Oncology, 2010
- Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancerLung Cancer, 2009
- Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trialThe Lancet Oncology, 2006
- The Impact of Dose Intensity of Standard Chemotherapy Regimens in Extensive Stage Small Cell Lung CancerAmerican Journal of Clinical Oncology, 1993